In LEUK 1 and LEUK2, SYRO is significantly more efficient than AR-C, to decrease leukemic cells viability (Figure 9C), both AML patients expressing high level of MCT4 (not shown). Here, SLC16A3 is linked to acute myeloid leukemia.